About Abbott India Limited

Abbott India Limited, incorporated in 1944, is a pharmaceutical company that combines world-class science with deep local insights to deliver medicines across India for over 80 years. The company’s core business is the manufacturing, marketing, sale, and distribution of pharmaceuticals, with a diverse portfolio spanning Gastroenterology, Women’s Health, Metabolics, Central Nervous System (CNS), Vaccines, and Multi-Specialty. 

Abbott India Limited’s Geographic Presence 

Abbott India operates nationally across 28 states and 8 union territories and also serves Sri Lanka, Nepal, Maldives, and Bhutan, supported by one manufacturing plant and multiple offices in India and abroad.

Abbott India Limited Key Brands 

Key brands in Abbott India’s portfolio include Creon, Cremaffin/Cremaffin Plus, Digene/Digeraft, Duphalac, Duphaston, Prothiaden, Duvadilan, Ganaton, Thyronorm, Heptral, Influvac, Librax, Udiliv, Vertin, and Zolfresh. In FY 2024–25, the company reported Revenue from Operations of Rs 6,409.15 crore and Profit for the Year of Rs 1,414.44 crore.

 Abbott India Limited’s Business Segments

• Operating divisions: Abbott India reports a single business segment—Pharmaceuticals—viewed by the Managing Director as the Chief Operating Decision Maker for resource allocation and performance assessment.

• Industries served: Pharmaceuticals account for 100% of the company’s turnover.

• Revenue by Geography: Sales are stated as “substantially” in the domestic market; no separate geographic revenue disclosure is provided.

• Revenue by Industry Vertical: No revenue split by therapeutic area is provided; the company discloses one reportable segment only.

 Abbott India Limited Key Management

• Munir Shaikh, Chairman (Non-Executive): Chairs the Board and committees guiding governance and oversight.

• Kartik Rajendran, Managing Director (appointed June 14, 2025): Leads overall strategy and operations; the Annual Report notes his transition into the role.

• Maithilee Mistry, Chief Financial Officer: Oversees financial management and reporting, as recorded in the financial statement signatories.

Latest Updates on Abbott India Limited

• Product launches in FY 2024–25 included Vonefi (PCAB), Digeraft Tablet, Digene Insta On The Go, Duphaston OD, Prothiaden Neu, Pneumoshield 14 (pneumococcal vaccine), and Citrosoda UTI, expanding offerings across GI, women’s health, neurology, vaccines, and urinary tract health. 
• The company reported that 8 brands rank among the Top 100 in the Indian Pharmaceutical Market (IPM), and 12 hold the No. 1 position in their respective participated markets (RPM).
• A partnership with Takeda was announced to bring Vonoprazan (for GERD) to market, reflecting an innovation-led approach. Key campaigns such as Vertin’s #ChakkarKoCheckKar and Digene’s #ControlKar received external recognition for patient awareness. The Board recommended a final dividend of Rs 475 per equity share for FY 2024–25, subject to shareholder approval at the AGM.